Compare Schlumberger NV (SLB) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs 10X Genomics Inc — how do they compare? Schlumberger NV trades at $49.07 (market cap $72.69B), while 10X Genomics Inc trades at $81.35 (market cap $10.07B). The key difference: Schlumberger NV is far larger — about 7.2× 10X Genomics Inc's market cap, and Schlumberger NV pays a 2.41% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Schlumberger NV for 99 Days and 10X Genomics Inc for 92 Days on average.
| SLB | TXG | |
|---|---|---|
Market Cap | $72.69B | $10.07B |
Volume | 16,228,451 | 5,657,286 |
Sector | Energy | Health |
52-Week High | $60.10 | $97.74 |
52-Week Low | $31.72 | $11.48 |
Typical Hold Time | 99 Days | 92 Days |
Enterprise Value | $81.42B | $9.59B |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB trades at $47.96, down 4.08% on the day, amid a bearish technical signal. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending. Recent contract wins in the Rovuma Basin, Saudi Arabia, and Oman bolster revenue visibility. Cash flow from operations remains strong at $6.49B for 2025, though net cash flow was negative due to financing activities.
Analyst consensus is bullish with an 84.85% buy rating and a $64.58 price target, implying significant upside. Risks include exposure to oil price volatility and recent profit margin compression. The stock's current valuation metrics, including a P/E of 23.89, appear reasonable given growth prospects.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
